| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Lian Brian | President & CEO, Director | C/O VIKING THERAPEUTICS, INC., 9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO | /s/ Michael Morneau, as Attorney-in-Fact | 2025-07-03 | 0001614578 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | VKTX | Common Stock, par value $0.00001 per share | Award | $0 | +48.3K | +2.04% | $0.00 | 2.41M | Jul 2, 2025 | Direct | F1 |
| transaction | VKTX | Common Stock, par value $0.00001 per share | Sale | -$748K | -26.9K | -1.11% | $27.80 | 2.39M | Jul 3, 2025 | Direct | F2, F3 |
| Id | Content |
|---|---|
| F1 | The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2025, 33.33% of which vested on July 2, 2025 upon the achievement of a non-financial performance goal. |
| F2 | These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.70 to $27.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote. |